Objective: To evaluate prospectively the value of the ‘repositioning test' (RT) in preoperative patient selection for the efficacy of male stress urinary incontinence (SUI) treatment using a retroluminar transobturator male sling (AdVance sling). Patients and Methods: 65 consecutive patients with SUI after radical prostatectomy were included in this single-center prospective study. Preoperatively, patients were classified into those with ‘positive' and ‘negative' RT. Postoperative results were analyzed and the association between the result of the RT and postoperative outcome was evaluated. Results: 53 patients (81.5%) showed preoperatively a positive RT and 12 patients (18.5%) a negative RT. After a follow-up of 12 months, patients with positive RT showed a cure rate (0 pads/day) of 83% and patients with a negative RT showed only a cure rate of 25%. A positive RT significantly correlated with cure in outcome (p < 0.001). Conclusions: Patients with positive RT have a significantly better chance for successful AdVance sling implantation. The RT is minimally invasive, easy to learn and easy to perform. Therefore, the RT is a very useful tool for preoperative patient selection.

Keywords:
Retroluminar transobturator male sling, Repositioning test, AdVance sling, Postprostatectomy stress urinary incontinence, Preoperative patient selection
1.
Bauer RM, Gozzi C, Hubner W, Nitti VW, Novara G, Peterson A, Sandhu JS, Stief CG: Contemporary management of postprostatectomy incontinence. Eur Urol 2011;59:985-996.
2.
Thuroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Schroder A, Tubaro A: EAU guidelines on urinary incontinence. Eur Urol 2011;59:387-400.
3.
Gozzi C, Becker AJ, Bauer R, Bastian PJ: Early results of transobturator sling suspension for male urinary incontinence following radical prostatectomy. Eur Urol 2008;54:960-961.
4.
Bauer RM, Mayer ME, May F, Gratzke C, Buchner A, Soljanik I, Bastian PJ, Stief CG, Gozzi C: Complications of the AdVance transobturator male sling in the treatment of male stress urinary incontinence. Urology 2010;75:1494-1498.
5.
Bauer RM, Soljanik I, Fullhase C, Buchner A, May F, Stief CG, Gozzi C: Results of the AdVance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. Urology 2011;77:474-479.
6.
Cornu JN, Sebe P, Ciofu C, Peyrat L, Cussenot O, Haab F: Mid-term evaluation of the transobturator male sling for post-prostatectomy incontinence: focus on prognostic factors. BJU Int 2011;108:236-240.
7.
Rehder P, Haab F, Cornu JN, Gozzi C, Bauer RM: Treatment of postprostatectomy male urinary incontinence with the transobturator retroluminal repositioning sling suspension: 3-year follow-up. Eur Urol 2012;62:140-145.
8.
Rehder P, Mitterberger MJ, Pichler R, Kerschbaumer A, Glodny B: The 1-year outcome of the transobturator retroluminal repositioning sling in the treatment of male stress urinary incontinence. BJU Int 2010;106:1668-1672.
9.
Rehder P, Freiin Von Gleissenthall G, Pichler R, Glodny B: The treatment of postprostatectomy incontinence with the retroluminal transobturator repositioning sling (AdVance): lessons learnt from accumulative experience (in Spanish). Arch Esp Urol 2009;62:860-870.
10.
Soljanik I, Gozzi C, Becker AJ, Stief CG, Bauer RM: Risk factors of treatment failure after retrourethral transobturator male sling. World J Urol 2012;30:201-206.
11.
Bauer RM, Mayer ME, Gratzke C, Soljanik I, Buchner A, Bastian PJ, Stief CG, Gozzi C: Prospective evaluation of the functional sling suspension for male postprostatectomy stress urinary incontinence: results after 1 year. Eur Urol 2009;56:928-933.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.